Products

Discover nanopore sequencing

What can it do? How does it work? Our platform performance and accuracy

Explore products

Prepare Sequence Analyse
Store Resources Support About

Products IVD Testing (COVID-19)

LamPORE COVID-19

A rapid, low-cost, highly scalable test for SARS-CoV-2

LamPORE COVID-19 is a complete and streamlined molecular diagnostic assay for routine detection of SARS-CoV-2, the virus that causes COVID-19. The assay is highly scalable, allowing deployment in both high-throughput, traditional laboratory settings as well as low-throughput laboratories and other locations where testing may be required — addressing the need for rapid and routine screening of large numbers of people.

LamPORE COVID-19 has been approved for diagnostic use in the UK only. Regulatory submissions for diagnostic usage in other countries and regions, including CE-IVD submission for Europe and FDA-Emergency Use Authorisation in the US, are in progress. For all other countries, view research products for SARS-CoV-2 analysis.

Benefits

Advantages of LamPORE Test

Real-time

Rapid and scalable

1 - 480 samples per run; up to XXX samples in 8 hours.

Cost-efficient

Cost-efficient

Consumable purchase only with minimal training, equipment, or hands-on time required.

Convenient format

Accurate

Targets three highly conserved SARS-CoV-2 genes, reducing inconclusive results and requirement for repeat testing.

Simple workflow

Reliable

Distinguish low-quality samples from true negatives using inbuilt control.

High specificity

Specific

Digital, sequence-based negative/positive result ensures higher specificity than achievable with colorimetric LAMP tests.

Workflow

Complete, end-to-end workflow

Automatable with optional LIMS integration.

GridION nanopore sequencing device

The Lampore Assay

A complete, end-to-end assay

The fully integrated workflow comprises a GridION OND device, with built-in analysis software, and consumables, including flow cells and LamPORE Covid-19 kits. The locked-down workflow allows processing of XXXX samples in 8 hours (or 1–480 samples in 2.5 hours) across up to five flow cells. Each flow cell can be addressed and run independently, offering highly flexible, demand-based testing.

Workflow

LamPORE workflow

The LamPORE COVID-19 assay is performed on extracted RNA from upper respiratory and saliva samples. The assay leverages reverse-transcription coupled to loop-mediated isothermal amplification (RT-LAMP) to amplify three highly conserved genes in SARS-CoV-2 positive samples (E gene, N gene, ORF1a) and a negative control gene (human actin).

Requiring a 30-minute incubation at 65ºC, isothermal amplification is a simple and fast method for amplifying a specific target, with no requirement for specialised equipment.

Following amplification, samples are prepared for analysis using Oxford Nanopore’s rapid sample preparation chemistry. Molecular barcode addition at both the amplification and sample preparation stages enables high multiplexing capacity to be achieved for large numbers of samples.

The prepared samples are loaded onto the GridION OND device and real-time analysis begins. When sequencing reads aligning to the SARS-CoV-2 genome and a control target reach a threshold number per sample, the sample can be classed as positive.

The human actin control should amplify in all correctly collected samples and enables the user to discriminate negative results due to sample collection errors rather than the absence of SARS-CoV-2 infection.

Analysis is performed automatically by the GridION OND device with no requirement for manual intervention or interpretation. Results are provided in visual and LIMS-compatible report formats, with the status of each sample clearly identified.

LamPORE COVID-19 Instructions for Use

View detailed protocol information, including consumable requirements and performance specifications.

Download
LamPORE Test Workflow
Figure 1: The fully integrated LamPORE COVID-19 workflow provides a simple, fast, and accurate method for detecting the presence of SARS-CoV-2 in a sample.

Performance

Specifications

LamPORE COVID-19 provides reliable and routine detection of SARS-CoV-2 from nasopharyngeal swabs. The assay targets three highly conserved regions of the SARS-CoV-2 genome (N gene; E gene; ORF1a), providing enhanced sensitivity and reducing inconclusive results and requirement for repeat testing.

Assay specifications

Sensitivity XXX
Specificity XXX
Limit of detection XXX

GridION OND device specifications

Size W 370 mm, H 220 mm, D 365 mm
Weight 11 Kg
On-board analysis Yes
LIMS compatible Yes
Scalable Run 1–5 flow cells independently (up to 96 samples per flow cell)
Register your interest

Subscribe

Get in touch


Talk to us

If you have any questions about our products or services, chat directly with a member of our sales team.

Talk to us

Book a sales call

To book a call with one of our sales team, please click below.

Book a call

Regulatory status

Product availability varies by country and is subject to local regulatory requirements.

Intended use

FDA-Emergency Use Only

CE-IVD

MinION Mk1C

In development

The LamPORE methodology is highly versatile and Oxford Nanopore is developing a number of product line extensions for potential regulatory submission, including:

  • Multiplexing of 1,152 samples per flow cell
  • Direct from saliva testing
  • Multi-pathogen detection
  • Portable analysis on the hand-held MinION Mk1C device
Register your interest
MinION Mk1C

COVID-19 research products

Discover how researchers are using nanopore sequencing to enhance our understanding of SARS-CoV-2 through:

  • Rapid whole genome sequencing
  • Direct RNA sequencing
  • Metagenomic sequencing
COVID-19 research